Takeda Says Rebates, Subsidies Cut $885M IBS Drug Verdict
Takeda Pharmaceuticals battled with a class of health plans over whether a Massachusetts federal jury's $885 million antitrust verdict against the drugmaker for conspiring to delay generic competition to anticonstipation drug...To view the full article, register now.
Already a subscriber? Click here to view full article